We are creating a unified UKRI website that brings together the existing research council, Innovate UK and Research England websites.
If you would like to be involved in its development let us know.

Hartree Centre in £20.4m collaboration

28 January 2016

ADDoPT logo

(Credit: ADDoPT)

A new major collaborative project is set to transform the UK pharmaceutical industry by enabling the manufacturing processes of the innovative medicines of the future to be designed digitally.

The STFC Hartree Centre is a partner in the £20.4m ADDoPT (Advanced Digital Design of Pharmaceutical Therapeutics) project, which involves major pharmaceutical companies, Pfizer, GSK, AstraZeneca and Bristol-Myers Squibb.

A four-year collaboration between government, industry and academia, the project addresses a key challenge for the pharmaceuticals industry; getting new innovative medicines to market in the quickest and most cost-effective way possible to ensure access for patients. It will achieve this by developing advanced digital design techniques that that eliminate non-viable drug candidate formulations as early as possible, streamlining design, development and manufacturing processes.

Part of the Science and Technology Facilities Council, and located at Sci-Tech Daresbury in Cheshire, the Hartree Centre’s world leading supercomputing facilities and expertise in big data analytics and computational chemistry will be applied to case studies, provided by the industrial pharmaceutical project partners, to achieve better design and predictive processes for innovative medicines.

ADDoPT group

The ADDoPT group at the kick off meeting in
late January 2016

Hartree Centre Business Development Manager for Life Sciences, Dr Adrian Toland, said: “The medicines industry is a major component of UK manufacturing sector with a turnover in excess of £31bn. The industry’s sustainability and future growth will be enhanced by responding to drivers such as the increasing demand for personalised medicines.

“We are extremely excited to be working with our major industrial project partners, as they seek to make innovative and more sophisticated medicines available to patients quicker and more cost effectively. Big data is an essential ingredient in the design and development of our society’s next generation of medicines, taking time and money out of the innovation process. The Hartree Centre’s world leading facilities and skills in data analytics and modelling are pivotal to the success of this project, which will secure the UK’s position at the forefront of new drug development.”

Adrian Toland and Christelle Gendrin from the STFC Hartree Centre explain how the ADDoPT (Advanced Digital Design of Pharmaceutical Therapeutics) project is aiming to address key challenges for the pharmaceutical industry, see video below.

ADDoPT | Big data analytics to transform UK pharmaceutical product development
(Credit: STFC)

Further information

Wendy Ellison
STFC Press Officer
Tel: 01925 603232 / 07919 548012

Any companies wanting to engage with the work of the Hartree Centre please contact:

Dr Adrian Toland
Business Development Manager, Hartree Centre
Tel: 01925 603241 / 07920275643

Photo available

The ADDoPT group

Information for editors

  1. The ADDoPT project is a £20.4m UK Government-Industry-Academia collaboration, part funded under the Advanced Manufacturing Supply Chain Initiative (AMSCI – see Note 2) running until March 2019. The full list of project partners includes:
     
    • Leading businesses in the pharmaceutical value supply chain – Pfizer Ltd, GlaxoSmithKline Plc, AstraZeneca UK Limited, and Bristol-Myers Squibb Pharmaceuticals Limited
       
    • Knowledge-driven small to medium sized enterprises (SMEs) – Process Systems Enterprise Ltd, Perceptive Engineering Ltd, and Britest Ltd
       
    • Specialist knowledge-based partners from UK universities and research centres – Cambridge Crystallographic Data Centre (CCDC), University of Leeds, University of Cambridge, STFC Hartree Centre, and the EPSRC’s Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation (CMAC) at the University of Strathclyde.

      ADDoPT partners will be working across the pharmaceutical value chain to define a system for the top-down, knowledge-driven Digital Design and Control of drug products and their manufacturing processes. This will bring together a wide range of predictive models and insight from industrial case studies at the four major pharmaceutical companies (Pfizer, GSK, AstraZeneca, and Bristol-Myers Squibb), allowing more targeted future experimentation, a better understanding of risk, and hence better design and scale-up for robust drug products and processes.

      The project is co-ordinated by Process Systems Enterprise Ltd (PSE), Project Manager Sean Bermingham, s.bermingham@psenterprise.com. The project was initiated by the Medicines Manufacturing Industry Partnership (MMIP - see Note 3).
       
  2. AMSCI supported manufacturing supply chains in England to reshore in the UK and improve global competitiveness by encouraging innovative, collaborative projects which established strong, sustainable and balanced growth. Complementing the Regional Growth Fund, AMSCI offered flexible funding support for R&D, skills, training, capital finance and leveraging private sector investment. AMSCI is administered by Finance Birmingham Limited.

    The ADDoPT project received a conditional offer of support under the Advanced Manufacturing Supply Chain Initiative (AMSCI) on 5 March 2015. An unconditional offer of support was ratified by the AMSCI Board on 27 November 2015. Formal project kick-off was 15 January 2016.
     
  3. The Medicines Manufacturing Industry Partnership (MMIP) was jointly established in September 2014 by the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA). The Partnership brings the biopharmaceutical industry together to work towards a common goal of creating an attractive and innovation-driven environment to ensure UK competitiveness in medicines manufacturing.

    The Knowledge Transfer Network (KTN) also played a key role in securing funding for the ADDoPT project and has worked closely with the MMIP since its establishment.
     
  4. A project website will be established shortly.

STFC Hartree Centre

Part of the STFC Daresbury Laboratory, and located within the Sci-Tech Daresbury science and innovation campus, the Hartree Centre is driving growth and innovation between science and industry using intense computing.

Every day, the Hartree Centre collaborates with industrial clients and research partners on projects that create insights and value using high performance computing, Big Data analytics, simulation and modelling. By combining one of the most powerful supercomputers in the world dedicated to industrial engagement with access to data scientists, engineers and software specialists, the Centre is enabling organisations of all sizes to produce better outcomes, products and services more quickly and cost-effectively than they can through conventional R&D workflows.

Underpinned by nearly £170m of Government funding, the Hartree Centre is enabling academics and industry within the UK and internationally to solve research challenges, establish competitive advantage and stimulate economic growth.

In partnerships, the Hartree Centre is also developing the next generation of supercomputing architectures and software, combining existing best practice with innovation to deliver faster, more energy sustainable solutions capable of meeting the challenges of data intensive computing.

Last updated: 17 September 2018

UKRI

Science and Technology Facilities Council
Switchboard: +44 (0)1793 442000